New hope for leukemia patients allergic to key chemo drug
NCT ID NCT00590915
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study offers Erwinase, a different form of chemotherapy, to children and adults with acute lymphoblastic leukemia (ALL) who have had allergic reactions to standard L-asparaginase drugs. The goal is to provide a safe treatment option for those who cannot use the usual medications. Participants must have confirmed ALL and a history of allergic reactions to certain asparaginase formulations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.